Pulmonary tuberculosis: Difference between revisions

From IDWiki
()
()
Line 23: Line 23:
 
** [[Is treated by::Pyrazinamide]] 25mg/kg/d, max 2g daily
 
** [[Is treated by::Pyrazinamide]] 25mg/kg/d, max 2g daily
 
** [[Is treated by::Ethambutol]] 20mg/kg/d, max 1.2g daily, which can be dropped once susceptibility testing shows that it is pan-susceptible
 
** [[Is treated by::Ethambutol]] 20mg/kg/d, max 1.2g daily, which can be dropped once susceptibility testing shows that it is pan-susceptible
* Standard duration for uncomplicated disease is 6 months, but should be extended to 9 months if high-risk (including smear positive at 2 months or cavitations)
+
* Standard duration for uncomplicated disease is 6 months total
  +
  +
=== Special populations ===
  +
* For the elderly, or those at elevated risk of hepatotoxicity: can do induction phase ''without'' [[pyrazinamide]] and extend continuation phase to 7 months (from 4)
  +
* For pregnant women: can consider dropping [[pyrazinamide]] and extending the course by 3 months, but if there is severe disease then likely should follow standard treatment
  +
* For high risk of relapse, including extensive or cavitary disease in the first 2 months of treatment, culture-positivity after 2 months of treatment, or cavitary disease on CXR at end of treatment: the consolidation phase should be extended by 3 months (to 9 months total treatment)
  +
* For severe liver disease:
  +
** Avoid [[rifampin]], [[isoniazid]], and [[pyrazinamide]]
  +
** Recommend a fluoroquinolone, [[ethambutol]], and [[amikacin]] for 2 months followed by fluroquinolone and ethambutol for 18 months
  +
** Can consider adding [[rifampin]] if they are monitored closely
  +
  +
=== Infection control ===
 
* Airborne precautions until:
 
* Airborne precautions until:
 
** Treated for at least 2 weeks
 
** Treated for at least 2 weeks

Revision as of 23:52, 13 November 2019

Background

Microbiology

Clinical Presentation

  • Presents as reactivation of latent infection months or years after primary tuberculosis
  • Subacute or chronic cough (at least 2 to 3 weeks) eventually becoming productive and occasionally involving hemoptysis
    • Should be suspected in any patient with cough and HIV infection
  • Constitutional symptoms, with fevers, night sweats, and unexplained weight loss
  • Usually from reactivation of latent tuberculosis infection, and usually reactivates in lung apices
  • May transiently improve with partially-active antibiotics such as fluoroquinolones

Investigations

  • Spontaneous sputum, induced sputum, or bronchoalveolar lavage specimens should be sent for
    • Acid-fast staining of a smear
    • Culture
    • PCR

Management

  • Standard HREZ x2mo then HR x4mo
    • Isoniazid 5mg/kg/d, max 300mg daily, with pyridoxine 25 mg po daily
    • Rifampin 10mg/kg/d
    • Pyrazinamide 25mg/kg/d, max 2g daily
    • Ethambutol 20mg/kg/d, max 1.2g daily, which can be dropped once susceptibility testing shows that it is pan-susceptible
  • Standard duration for uncomplicated disease is 6 months total

Special populations

  • For the elderly, or those at elevated risk of hepatotoxicity: can do induction phase without pyrazinamide and extend continuation phase to 7 months (from 4)
  • For pregnant women: can consider dropping pyrazinamide and extending the course by 3 months, but if there is severe disease then likely should follow standard treatment
  • For high risk of relapse, including extensive or cavitary disease in the first 2 months of treatment, culture-positivity after 2 months of treatment, or cavitary disease on CXR at end of treatment: the consolidation phase should be extended by 3 months (to 9 months total treatment)
  • For severe liver disease:

Infection control

  • Airborne precautions until:
    • Treated for at least 2 weeks
    • 3x negative sputum smears, which can be collected hourly, but ideally at 8- to 24-hour intervals, including one early morning collection
    • Improvement in symptoms